Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease
Glen A Doherty, Mark A PeppercornCenter for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston MA, USAAbstract: 5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative colitis (UC). A range of 5-ASA preparations is ava...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-12-01
|
| Series: | Clinical and Experimental Gastroenterology |
| Online Access: | http://www.dovepress.com/update-on-the-role-of-modified-release-mesalamine-in-the-management-of-a3813 |